FOXM1 confers acquired cisplatin resistance in breast cancer cells
about
sameAs
Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytesPhosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cellsSustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasisThe Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to TherapyFOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistanceExploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cellsPeroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cellsNext-generation transcriptome sequencing of the premenopausal breast epithelium using specimens from a normal human breast tissue bank.FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cellsFOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancerIntegration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.Increased FOXM1 expression can stimulate DNA repair in normal hepatocytes in vivo but also increases nuclear foci associated with senescence.FoxM1 mediates resistance to herceptin and paclitaxel.FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage.Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma.Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistanceRestoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.Suppression of the FOXM1 transcriptional programme via novel small molecule inhibitionMammary glands exhibit molecular laterality and undergo left-right asymmetric ductal epithelial growth in MMTV-cNeu mice.Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cellsSorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNAFoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.Small molecule inhibition of FOXM1: How to bring a novel compound into genomic contextPaclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.FoxM1 regulates mammary luminal cell fateOTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistanceThe p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment.JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.Identification of thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells.Forkhead box protein M1 predicts outcome in human osteosarcomaA Gene Regulatory Program in Human Breast CancerA Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS
P2860
Q21245703-9BE8A298-1E63-424B-BCBF-8EBCEB1633EDQ24301472-B2ABC4D5-459C-46BA-A823-4DDCD2838CB3Q24613046-5A7E6F4D-E7A4-4DB1-A451-383083ABBD86Q26768290-9E2E7553-88E8-4D72-AE54-1DAA8FE2852DQ26864654-D0B15C7D-C067-4BE0-AD69-B192983B560DQ28276344-187EF84B-C6C3-4616-81AC-4EE214AB278CQ28485231-DE7BDF97-213D-4283-927B-F9E1D41360EAQ28728015-294D71D4-F13A-4323-8A29-F1B707FAEB6AQ33456377-044C797B-0E00-4157-B7AD-E2B34D5DA6CAQ33567379-37A54D6E-2EB5-4344-841F-8F7425BB663BQ33605013-9F8A10EB-78C2-4A89-9AEA-C903FA21F48DQ33670486-50BFA79E-281F-42D6-B394-7FCD4AB830C5Q33924107-31A52838-BCA5-4CA0-87E0-4958F51D79CBQ33946664-8E9C40EE-4856-4FAB-8452-8CF0B1DDD125Q33991617-CCBAAC75-04EF-46E8-B5E2-CAC26D974AD9Q34000057-544EC7AE-399A-4E05-AE01-18E17C9F1DE2Q34185710-1BC01D6A-EA91-4AF5-A32D-A438E8585128Q34227706-C62466F2-E0F9-46A9-8B0D-F6071EAEC814Q34550042-879E0A85-964C-4E0B-B096-A99D554F971DQ34573492-11D9E70F-A21F-4DAD-AB42-2491CCEB9602Q34649774-8B61788B-C34E-426F-AD59-83BC0661561FQ34664059-B035D4A4-1CB6-4068-93E9-301939D12FADQ34956879-45EBAA28-F077-4F3D-BBAE-DE30FA9ECA31Q35080145-8305AA2A-54C0-4D66-8A17-D63EE312D79BQ35168154-55793625-5FFA-44E6-8698-7C85969C8763Q35273654-AAB57483-3F5B-47C4-B170-E165D1A09A65Q35410253-08B5A596-7D6D-47B2-9B5C-A83190294979Q35764362-D207119F-84FE-42BC-A827-5EE5D2CE335FQ35793788-7487A4A4-0D6A-4453-B9AB-B8B651BF0116Q35800767-45927E5D-4809-4CC7-A636-394AD8E77DD4Q35951768-95B06D9B-4461-4AEB-BB49-A7B9134D4589Q35962063-93226906-2F1C-4B83-AF16-C7113045E731Q36106731-8F3A00C9-2C33-42FE-923A-6E0F62D3CA31Q36165185-7D276212-5B88-4F23-B141-D17FAC41A814Q36249356-0E615DA0-8A36-4E8E-8378-3B8246DB4F82Q36291991-E594548B-C9AA-4437-9CB4-CF33F6A7C55EQ36293810-4D20B7B0-1262-4059-A3B9-5C38796EB0ACQ36317582-0FD83CB5-D308-422B-B2DA-D1FBEB4E23D2Q36365236-F0699744-B8FB-46D3-9528-8C0804FBEF3EQ36419222-E2BC1676-CD4D-4C41-BE96-B35577784214
P2860
FOXM1 confers acquired cisplatin resistance in breast cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@ast
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@en
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@nl
type
label
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@ast
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@en
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@nl
prefLabel
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@ast
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@en
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@nl
P2093
P2860
P3181
P1476
FOXM1 confers acquired cisplatin resistance in breast cancer cells
@en
P2093
Helma D C Schwenen
Jimmy M-M Kwok
Julie Millour
Lara J Monteiro
R Charles Coombes
Stephen S Myatt
P2860
P3181
P356
10.1158/1541-7786.MCR-09-0432
P407
P577
2010-01-01T00:00:00Z